News

Current Topic: Press Release

IMBRIUM THERAPEUTICS PRESENTS FIRST DATA AND DESCRIBES NOVEL MECHANISM OF ACTION FOR IMB-115, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR INSOMNIA DISORDER, AT 34^th ANNUAL SLEEP MEETING

IMBRIUM THERAPEUTICS L.P. AND SPINETHERA, INC. ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL STUDY

Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis/Bladder Pain Syndrome
Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Imbrium Therapeutics L.P. Exercising Option with PureTech Health to Develop and Commercialize a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment

Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
Imbrium Therapeutics L.P. and SpineThera Announce Issuance of U.S. Patent Covering Composition of Matter Protection for SX600, a Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Imbrium Therapeutics Advances Insomnia Pipeline Through Initiation of a Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
Imbrium Therapeutics Announces U.S. FDA Orphan Drug Designation for Tinostamustine for the Treatment of T-cell Prolymphocytic Leukemia
Imbrium Therapeutics Announces Enrollment of the First Patient in Expansion Phase of Tinostamustine Trial in Patients with Difficult-to-Treat Blood Cancers